| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2966944 | Journal of Clinical Lipidology | 2008 | 10 Pages |
Abstract
In real-world clinical practice, pharmacologic treatment rates increased upon assessment of multiple lipid abnormalities and by total risk factors for CHD. However, mixed dyslipidemia remained undertreated with low rates of niacin and fibrate usage.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Peter P. MD, PhD, Victoria PharmD, Jane M. MPH, Dave MPH,